GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EV-to-EBIT

ME Therapeutics Holding (XCNQ:METX) EV-to-EBIT : -14.89 (As of May. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ME Therapeutics Holding's Enterprise Value is C$103.19 Mil. ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$-6.93 Mil. Therefore, ME Therapeutics Holding's EV-to-EBIT for today is -14.89.

The historical rank and industry rank for ME Therapeutics Holding's EV-to-EBIT or its related term are showing as below:

XCNQ:METX' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.81   Med: 0   Max: 0
Current: -14.89
XCNQ:METX's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs XCNQ:METX: -14.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ME Therapeutics Holding's Enterprise Value for the quarter that ended in Feb. 2024 was C$102.64 Mil. ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$-6.93 Mil. ME Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -6.75%.

ME Therapeutics Holding EV-to-EBIT Historical Data

The historical data trend for ME Therapeutics Holding's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding EV-to-EBIT Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
EV-to-EBIT
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
EV-to-EBIT Get a 7-Day Free Trial - - - -1.67 -14.82

Competitive Comparison of ME Therapeutics Holding's EV-to-EBIT

For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's EV-to-EBIT falls into.


ME Therapeutics Holding EV-to-EBIT Calculation

ME Therapeutics Holding's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=103.187/-6.928
=-14.89

ME Therapeutics Holding's current Enterprise Value is C$103.19 Mil.
ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ME Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 ) =EBIT / Enterprise Value (Q: Feb. 2024 )
=-6.928/102.6448
=-6.75 %

ME Therapeutics Holding's Enterprise Value for the quarter that ended in Feb. 2024 was C$102.64 Mil.
ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EV-to-EBIT
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines